BOZEMAN, MT, December 31, 2009
/24-7PressRelease/ -- BioScience Laboratories announces efficacy and safety testing capabilities to support Health Canada's guidance document
Human-Use Antiseptic Drugs finalized on December 2, 2009. BioScience Laboratories actively participated in the development and revision of this document. The organization's Clinical and In-Vitro Laboratories have the training and experience to conduct the testing methods in accordance with CEN, ASTM, and ICH guidelines, as required in this document to show product efficacy and safety. BioScience Laboratories' GCP and GLP compliant quality system ensures that the testing documentation generated will meet Health Canada's requirements for submission to support product efficacy and safety claims.
For more information on BioScience Laboratories' capabilities to perform the testing outlined in the Health Canada
Human-Use Antiseptic Drugs guidance document, contact:
John Dyba
Senior Account Executive
1-877-858-2754
jdyba@biosciencelabs.com
http://www.biosciencelabs.comAbout BioScience Laboratories, Inc.
BioScience Laboratories, Inc. was founded in 1991 in Bozeman, MT, to provide antimicrobial product testing and result interpretation grounded in science. Bioscience Laboratories Inc. strives to assist its clients in strengthening their current market positions through product testing and aid in the development of new products and new markets. Today, BioScience Laboratories offers a variety of state-of-the-art laboratory services and guidance regarding federal regulatory agency requirements for the healthcare, pharmaceutical, personal care and consumer products markets.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com# # #
Press Release Keywords:- health canada, health canada guidance document, human-use antiseptic drugs, health canada human-use antiseptic drugs, product efficacy, product safety, efficacy testing, safety testing, bioscience laboratories, bozeman, anitiseptic drugs, antimicrobial drugs
Read more Press Releases from John Dyba:
